G-15: Selective GPR30 Antagonist for Estrogen Signaling Research

Executive Summary: G-15 (CAS 1161002-05-6) is a potent, selective antagonist of the G protein-coupled estrogen receptor (GPR30/GPER), exhibiting a Ki of ~20 nM and showing minimal activity against ERα/ERβ even at high concentrations (APExBIO). It dose-dependently inhibits G-1-induced calcium mobilization in cell models (IC₅₀ ≈ 185 nM) and reverses GPR30-mediated cell proliferation (Chen et al., 2024). In vivo, G-15 impairs spatial learning in ovariectomized rats, indicating its specificity for GPR30 signaling. Recent studies implicate GPR30 in neuropathic pain pathways, with G-15 providing a validated tool for mechanistic interrogation (Chen et al., 2024). G-15 is insoluble in water and ethanol but highly soluble in DMSO (≥37 mg/mL), facilitating robust use in both cellular and animal models.

Biological Rationale

The G protein-coupled estrogen receptor (GPR30/GPER) is a non-classical estrogen receptor that localizes to intracellular membranes, particularly the endoplasmic reticulum (APExBIO). Unlike ERα and ERβ, GPR30 mediates rapid non-genomic signaling in response to estrogens and selective agonists such as G-1. This signaling involves intracellular calcium mobilization, PI3K/Akt activation, and modulation of downstream pathways critical in cell proliferation, neurobiology, and pain processing (Chen et al., 2024). GPR30 is notably upregulated in spinal cholecystokinin-positive (CCK+) neurons during neuropathic pain, where it contributes to aberrant sensory processing and pain states.

Mechanism of Action of G-15

G-15 is a synthetic, non-steroidal small molecule characterized by the chemical name (3aR,4S,9bS)-4-(6-bromobenzo[d][1,3]dioxol-5-yl)-3a,4,5,9b-tetrahydro-3H-cyclopenta[c]quinoline (APExBIO). It selectively antagonizes GPR30, binding with high affinity (Ki ≈ 20 nM) and blocking GPR30-mediated intracellular signaling cascades. G-15 inhibits estrogen- or G-1-induced increases in intracellular calcium and suppresses PI3K activation, leading to reduced phosphorylation of Akt. Importantly, G-15 does not significantly interact with classical nuclear estrogen receptors ERα or ERβ, even at concentrations exceeding 10 μM, ensuring specificity for GPR30-mediated events (Related Article).

Evidence & Benchmarks

• G-15 binds GPR30 with a Ki of approximately 20 nM, demonstrating high selectivity (APExBIO).
• In cell-based assays, G-15 dose-dependently inhibits G-1-induced calcium mobilization (IC₅₀ ≈ 185 nM) (APExBIO).
• G-15 does not affect ERα/ERβ at concentrations up to 10 μM, confirming minimal cross-reactivity (America Peptide).
• In ovariectomized female rats, G-15 administration impairs spatial learning acquisition, supporting its in vivo specificity for GPR30 (APExBIO).
• In chronic constriction injury (CCI) mouse models, GPR30 upregulation in spinal CCK+ neurons is functionally linked to neuropathic pain; G-15 reverses CCI-induced allodynia (Chen et al., 2024).
• G-15 is insoluble in water or ethanol but is soluble in DMSO at ≥37 mg/mL, enabling preparation of concentrated stock solutions for cell culture or animal studies (APExBIO).

This work updates and extends prior overviews by providing direct links between G-15’s mechanism and disease models, unlike America Peptide, which focuses on in vitro specificity.

Applications, Limits & Misconceptions

Applications:

• Dissecting GPR30-mediated signaling in estrogen research, including rapid calcium signaling and PI3K/Akt pathway modulation.
• Modeling GPR30 involvement in neuropathic pain using rodent chronic constriction injury models (Chen et al., 2024).
• Investigating non-genomic estrogen actions in cancer biology, neurodegenerative disease, and cardiovascular models.
• Evaluating GPR30’s role in spatial learning and memory, particularly in postmenopausal and ovariectomized models.

Limits & Misconceptions:

Common Pitfalls or Misconceptions

• G-15 is not a pan-estrogen receptor antagonist: It has minimal affinity for ERα and ERβ and does not block classical nuclear estrogen signaling.
• Solubility is DMSO-dependent: G-15 is insoluble in aqueous buffers and ethanol; improper solvents lead to precipitation and unreliable dosing.
• Short-term solution stability: Prepared DMSO solutions should be stored below -20°C and used promptly to avoid degradation.
• Species and cell-type specificity: Efficacy benchmarks are primarily validated in rodent and human-derived cells; cross-species extrapolation requires independent validation.
• Not for direct therapeutic use: G-15 is strictly for research; it is not approved for human or veterinary treatment.

This article clarifies experimental boundaries and workflow integration, extending the application details discussed in Eprinomectinlab, which provides scenario-driven guidance for cell-based assays.

Workflow Integration & Parameters

G-15 is supplied as a solid by APExBIO (SKU B5469). Stock solutions are prepared in DMSO at concentrations >10 mM; warming to 37°C or sonication improves solubility (APExBIO). For cell culture, working concentrations typically range from 100 nM to 10 μM, depending on assay sensitivity. In animal studies, dosing regimens should consider compound stability, delivery route, and pharmacokinetics. Solutions must be stored at <-20°C and protected from light. G-15 is compatible with standard calcium mobilization, Western blotting, and behavioral assay workflows. For advanced signaling dissection, it may be paired with G-1 (agonist) in parallel arms to validate antagonist specificity. For further workflow details, see G-Protein Coupled Receptor Resource, whose content focuses on non-genomic signaling assays—this article expands with in vivo benchmarks and solubility protocols.

Conclusion & Outlook

G-15 is a validated, selective GPR30 antagonist for dissecting estrogen signaling, calcium mobilization, and PI3K/Akt pathway regulation. Its selectivity and robust solubility in DMSO make it suitable for diverse biomedical research applications. The compound is central in both neurobiology and cancer signaling studies, as well as in translational pain models. As evidence for GPR30’s role in neuropathic pain and other disease states grows, G-15 provided by APExBIO is expected to remain indispensable for mechanistic and therapeutic research.